Clinical trials: Dermatitis Atopic
Atopic Dermatitis
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion.
- Trial name
- IGUANA (NCT03568071)
- Testing
- MOR 106
- Where
- 53 sites in Germany, Hungary and 3 more
- Volunteers
- 207 people
- Sponsor
- Lakefront Biotherapeutics NV
Dermatitis, Atopic
Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients
Objective: Assess efficacy and safety of tacrolimus ointment when used in adults with moderate or severe atopic dermatitis. The ointment was applied on the affected skin twice daily for 3 weeks and then once daily until all…
- Trial name
- NCT00523952
- Testing
- tacrolimus ointment
- Where
- 25 sites in Czechia, Hungary and 1 more
- Volunteers
- 303 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Dermatitis Atopic
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus.
- Trial name
- DIFFEREN-STAD (NCT04823130)
- Testing
- Dupilumab (SAR231893)
- Where
- 3 sites in United States, Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis, Atopic
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05544591
- Testing
- 611 Q2W, 611 Q4W
- Where
- 5 sites in China
- Volunteers
- 93 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis
Atopic dermatitis represents a real challenge in public health as it affects a large percentage of children and adults. Affected individuals must cope with a significant psychosocial burden, in addition to dealing with the…
- Trial name
- NCT04553224
- Testing
- Clinical evaluations, Non-invasive instrumental measurements, Subject's evaluations
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
This is a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis.
- Trial name
- NCT04307862
- Testing
- ZEP-3Na 0.1%, ZEP-3Na 1%
- Where
- 10 sites in Israel
- Volunteers
- 165 people
- Sponsor
- Shulov Innovate for Science Ltd. 2012
Mild to Moderate Atopic Dermatitis
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Atopic dermatitis (AD) is a chronic or chronic recurring inflammatory skin disorder. Patients suffer from eczema and often severe pruritus on the affected skin, as well as from frequent complications and secondary infections.
- Trial name
- NCT02079688
- Testing
- SB011, 2 % (Water/Oil/Water) emulsion of hgd40, Multiple W/O/W formulation, active ingredient-free vehicle
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Atopic Dermatitis
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis.
- Trial name
- NCT05142774
- Testing
- Tapinarof cream, 1%
- Where
- 112 sites in United States, Canada
- Volunteers
- 728 people
- Sponsor
- Organon and Co
Smallpox, Atopic Dermatitis
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
- Trial name
- NCT00389103
- Testing
- MVA (smallpox vaccine)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Atopic Dermatitis (AD)
A Phase III Study of GS101 Injection to Dupixent®
This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07386743
- Testing
- GS101 injection, DUPIXENT®
- Where
- China
- Volunteers
- 572 people
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Eczema, Atopic Dermatitis
NPQ Plus Supplementation for Skin Health and Antioxidant Status
This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns.
- Conditions
- Eczema, Atopic Dermatitis, Skin Health, Fatigue Symptom
- Trial name
- NCT07703215
- Testing
- NPQ Plus
- Where
- Malaysia
- Volunteers
- 55 people
- Sponsor
- N REMEDIER (M) SDN BHD
Atopic Dermatitis
Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis
This is a Phase 2b, multi-center, randomized, double-blind, vehicle-controlled, intraparticipant study to evaluate efficacy and safety of two regimens of crisaborole ointment 2% in Japanese pediatric and adult participants…
- Trial name
- NCT03954158
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- 3 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Pfizer
Atopic Dermatitis
Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic…
- Trial name
- NCT03091426
- Testing
- Omiganan
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maruho Co., Ltd.
Asthma, COPD
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
This is a Phase 1, randomized, placebo-controlled study, enrolling approximately 38 healthy adult subjects (18-65 yrs). The purpose of this study is to evaluate the safety, tolerability and PK of single ascending dose of 9MW1911…
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05170243
- Testing
- 9MW1911 Injection
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Dermatitis, Atopic, Eczema
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT04800315
- Testing
- CC-93538
- Where
- 157 sites in United States, Canada and 4 more
- Volunteers
- 221 people
- Sponsor
- Celgene
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
This is a randomized, double-blind, placebo-controlled Phase Ib clinical trial evaluating the safety tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR2002 Injection in patients with moderate to severe…
- Trial name
- NCT06175143
- Testing
- GR2002 injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Atopic Dermatitis
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
The purpose for this study is to assess the Safety and Efficacy of Daily Application for 4 weeks of DBI-001 Gel Versus Aqueous Gel in Subjects with Atopic Dermatitis
- Trial name
- NCT05253755
- Testing
- DBI-001, Aqueous gel
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- NCT06181435
- Testing
- Amlitelimab
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 589 people
- Sponsor
- Sanofi
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- COAST 1 (NCT06130566)
- Testing
- Amlitelimab
- Where
- 148 sites in United States, Argentina and 13 more
- Volunteers
- 601 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.